HGH Frag · Fragment 176-191
Lipolytic GH fragment — pure fat burning without growth effects.
FDA
Research Only
WADA
Not Listed
HALF-LIFE
~30 minutes
ROUTE
SubQ injection
SCHEDULE
Daily
In Plain English
Lipolytic GH fragment — pure fat burning without growth effects.
Status & Legality
NATTY?
No Test ExistsNo established test exists for this compound.
FDA
Research OnlyFor research purposes only. Not FDA approved.
WADA
Not ListedNot currently on WADA prohibited list.
COMPOUNDING
Not from pharmaciesNot available from licensed compounding pharmacies.
PRESCRIBED
Not prescribedNot prescribed in conventional medicine.
ROUTE
SubQ injectionAdministration via subq injection.
Fat loss
Lipolysis
Stubborn fat reduction
HGH Fragment 176-191 is the C-terminal end of human growth hormone, specifically isolated for its fat-burning properties. Unlike full HGH, it doesn't raise IGF-1 or affect blood glucose, making it safer for metabolic use. It works by regulating fat metabolism through a mechanism distinct from the GH receptor.
Injection site redness
Drowsiness (rare)
Well tolerated overall
Expecting the anabolic or IGF-1-raising effects of full HGH — this fragment specifically lacks those effects; it's purely lipolytic
Not splitting the dose — the very short half-life means a single daily dose covers a narrow window; split AM + pre-workout
Eating within 30 minutes of injection — the fasting requirement for the lipolytic effect is strict
Insulin — fasted injection means blood glucose should be available; hypoglycemia is rare but possible at high doses
GH secretagogues (CJC/Ipamorelin) — commonly combined; generally safe and synergistic for fat loss
Semaglutide — different mechanisms; can be combined in a comprehensive fat loss protocol
HGH Frag is the 'safe' version of HGH fat burning — no IGF-1 elevation, no glucose effects, just the lipolytic mechanism. Results are meaningful but modest. Best used as part of a broader protocol that includes caloric control and GH secretagogues at night for sleep and recovery benefits.
Stats
Sources & Studies
Ng FM. et al., Mol Cell Endocrinol, 1990